Shanghai-based biotech Harbour BioMed has raised $85 million (€73 million). The series B equips a leadership team that cut its teeth at top multinational drugmakers to advance autoimmune and cancer candidates through the clinic.

Harbour emerged in late in 2016 helmed by ex-Sanofi executives. Led by Jingsong Wang, M.D., Ph.D., Harbour pulled in $50 million from Chinese VCs and bought an Atlas Venture-backed antibody shop with operations in the U.S. and the Netherlands. Harbour added to its series A haul at the start of the year, positioning it to license the rights to two oncology programs.

That done, Harbour has secured a further $85 million to execute the next stage of its plan. GIC Private Limited, Singapore's sovereign wealth fund, led the round. The money will support clinical development of a HER2-CD3 bispecific antibody and an anti-PD-L1 checkpoint inhibitor.